Bertrand Anz
Impact in
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 12
- Chronic Lymphocytic Leukemia Research 12
- Hematology 11
- Multiple Myeloma Research and Treatments 6
- Chronic Myeloid Leukemia Treatments 3
- Acute Myeloid Leukemia Research 2
- Co-authors
- Ian W. Flinn (12 shared papers)Carol Moreno (6 shared papers)Loree Larratt (5 shared papers)Richard Greil (5 shared papers)John G. Gribben (6 shared papers)Devinder Gill (6 shared papers)Alessandra Tedeschi (6 shared papers)Fatih Demırkan (6 shared papers)
- Journals
- Blood (11 papers)Hematological Oncology (2 papers)Clinical Breast Cancer (1 paper)HemaSphere (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Bertrand Anz
20 papers receiving 549 citations
Bertrand Anz's Hit Papers
Peers
Comparison fields: 5 of 32
- Genetics 470
- Pathology and Forensic Medicine 313
- Hematology 151
- Immunology 136
- Gastroenterology 25
Countries citing papers authored by Bertrand Anz
This map shows the geographic impact of Bertrand Anz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Anz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Anz more than expected).
Fields of papers citing papers by Bertrand Anz
This network shows the impact of papers produced by Bertrand Anz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Anz. The network helps show where Bertrand Anz may publish in the future.
Co-authors
The 25 scholars most cited alongside Bertrand Anz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2018 | 386 |
| 2 | 2022 | 83 | |
| 3 | 2022 | 17 | |
| 4 | 2021 | 9 | |
| 5 | 2019 | 8 | |
| 6 | 2018 | 7 | |
| 7 | 2024 | 7 | |
| 8 | 2019 | 7 | |
| 9 | 2018 | 5 | |
| 10 | 2023 | 5 | |
| 11 | 2019 | 4 | |
| 12 | 2021 | 3 | |
| 13 | 2020 | 3 | |
| 14 | 2019 | 3 | |
| 15 | 2018 | 2 | |
| 16 | 2020 | 2 | |
| 17 | 2023 | 1 | |
| 18 | 2023 | 1 | |
| 19 | 2021 | 1 | |
| 20 | 2020 | 1 |
About Bertrand Anz
Bertrand Anz is a scholar working on Genetics, Hematology, Oncology, Pathology and Forensic Medicine and Molecular Biology, having authored 21 papers that have together received 555 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (6 papers), Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Protein Degradation and Inhibitors (3 papers), Acute Myeloid Leukemia Research (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Genetics (470 citations), Pathology and Forensic Medicine (313 citations), Hematology (151 citations), Immunology (136 citations) and Gastroenterology (25 citations). Bertrand Anz has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Ian W. Flinn, Carol Moreno, Loree Larratt, Richard Greil, John G. Gribben, Devinder Gill, Alessandra Tedeschi, Fatih Demırkan, Martin Šimkovič and Emily Hsu. Their work appears in journals such as Blood, Hematological Oncology, Clinical Breast Cancer, HemaSphere and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.